Literature DB >> 26306928

Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms.

Valeria Schonstedt1, Ximena Stecher2, Viviana Venegas3, Claudio Silva2.   

Abstract

Vigabatrin is an antiepileptic drug used for treatment of infantile spasms. We present a female patient with infantile spasms in treatment with vigabatrin who developed ataxic movements. MRI demonstrated a symmetrical pattern of thalamic and globi pallidi diffusion restriction. While these image features have been widely described to be related to the use of vigabatrin, this case highlights the development of movement disorders in association with MRI signal changes. Awareness of the reversible nature of this condition is reassuring for the treating team and avoids unjustified studies.
© The Author(s) 2015.

Entities:  

Keywords:  Vigabatrin; ataxic movements; infantile spasms; magnetic resonance imaging

Mesh:

Substances:

Year:  2015        PMID: 26306928      PMCID: PMC4757222          DOI: 10.1177/1971400915598082

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  7 in total

Review 1.  Non-vision adverse events with vigabatrin therapy.

Authors:  S D Walker; R Kälviäinen
Journal:  Acta Neurol Scand Suppl       Date:  2011

Review 2.  Recent advances in the pharmacotherapy of infantile spasms.

Authors:  Raili Riikonen
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

3.  Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms.

Authors:  Aphrodite Dracopoulos; Elysa Widjaja; Charles Raybaud; Carol A Westall; O Carter Snead
Journal:  Epilepsia       Date:  2010-04-02       Impact factor: 5.864

Review 4.  The potential for vigabatrin-induced intramyelinic edema in humans.

Authors:  J A Cohen; R S Fisher; M G Brigell; R G Peyster; G Sze
Journal:  Epilepsia       Date:  2000-02       Impact factor: 5.864

Review 5.  Favourable prognostic factors with infantile spasms.

Authors:  Raili S Riikonen
Journal:  Eur J Paediatr Neurol       Date:  2009-04-11       Impact factor: 3.140

6.  Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms?

Authors:  Patricia Dill; Alexandre N Datta; Peter Weber; Jacques Schneider
Journal:  Eur J Paediatr Neurol       Date:  2012-11-27       Impact factor: 3.140

7.  An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms.

Authors:  Choong Yi Fong; John P Osborne; Stuart W Edwards; Cheryl Hemingway; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Rachel Kneen; Marcus Likeman; Andrew L Lux; Santosh R Mordekar; Velayutham Murugan; Richard W Newton; Michael Pike; Michael Quinn; Stefan Spinty; Grace Vassallo; Christopher M Verity; Andrea Whitney; Finbar J K O'Callaghan
Journal:  Dev Med Child Neurol       Date:  2013-06-22       Impact factor: 5.449

  7 in total
  7 in total

1.  Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis.

Authors:  Joseph Franklin Craft; Agustin M Cardenas
Journal:  J Radiol Case Rep       Date:  2021-02-28

Review 2.  The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.

Authors:  Paul LaPenna; Laura M Tormoehlen
Journal:  J Med Toxicol       Date:  2017-08-16

Review 3.  Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.

Authors:  Rima Nabbout; Mathieu Kuchenbuch; Catherine Chiron; Paolo Curatolo
Journal:  CNS Drugs       Date:  2021-08-21       Impact factor: 5.749

4.  2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.

Authors:  Adam D Kennedy; Kirk L Pappan; Taraka Donti; Mauricio R Delgado; Marwan Shinawi; Toni S Pearson; Seema R Lalani; William E Craigen; V Reid Sutton; Anne M Evans; Qin Sun; Lisa T Emrick; Sarah H Elsea
Journal:  Front Neurosci       Date:  2019-05-08       Impact factor: 4.677

5.  Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.

Authors:  Dana C Walters; Erwin E W Jansen; Garrett R Ainslie; Gajja S Salomons; Madalyn N Brown; Michelle A Schmidt; Jean-Baptiste Roullet; K M Gibson
Journal:  Pharmacol Res Perspect       Date:  2019-01-07

6.  Effectiveness of ACTH in Patients with Infantile Spasms.

Authors:  Justyna Paprocka; Jakub Malkiewicz; Veronica Palazzo-Michalska; Barbara Nowacka; Mikołaj Kuźniak; Ilona Kopyta
Journal:  Brain Sci       Date:  2022-02-11

7.  Modulation of vigabatrin induced cerebellar injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways.

Authors:  Marwa Abd El-Kader; Eman Hamza; Randa El-Gamal; Amira Sobhy Rashed Eladl; Eman Mohamad El Nashar; Mansour A Alghamdi; Omnia S Erfan
Journal:  J Mol Histol       Date:  2021-05-27       Impact factor: 2.611

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.